467 S.E.2d 610 | Ga. Ct. App. | 1996
Defendant was charged in an indictment with a single violation of the Georgia Controlled Substances Act, in that she did unlawfully “acquire and obtain possession of a controlled substance, to wit: DARVOCET/N-100 (DEXTROPROPOXPHENE [sic], SCHEDULE
The jury found defendant guilty. Her motion to “set aside the jury verdict . . .” was denied and this appeal followed. Held:
In her sole enumeration of error, defendant contends the trial court erred in denying her motion for directed verdict of acquittal “due to the State’s failure to link the drug listed in the Indictment (Darvocet) with the actual listed Schedule IV drug (Dextropropoxyphene).” We disagree.
Defendant correctly argues that mere proof of a trade name for a controlled substance is insufficient evidence to sustain a conviction under the Georgia Controlled Substances Act. Elrod v. State, 143 Ga. App. 331 (2) (238 SE2d 291). OCGA § 16-13-28 (a) (9) specifies “Dextropropoxyphene” as a Schedule IV controlled substance, and that is the controlled substance alleged in this indictment. Dorland’s Illustrated Medical Dictionary (24th ed. 1965) defines propoxyphene as “dextropropoxyphene.” For purposes of the Georgia Controlled Substances Act, dextropropoxyphene and propoxyphene are chemically identical analgesics. In the case sub judice, the evidence showed that Darvocet N-100 is propoxyphene with acetaminophen and dextropropoxyphene is “Propoxyphene Napsylate.” In the absence of any countershowing, this circumstantial evidence was sufficient under the standard of Jackson v. Virginia, 443 U. S. 307 (99 SC 2781, 61 LE2d 560) to authorize the jury’s determination that the 90 Darvocet N-100 tablets defendant fraudulently obtained were in fact the controlled substance dextropropoxyphene as alleged in the indictment, beyond any reasonable doubt. The enumeration of the general grounds is without merit.
Judgment affirmed.